Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED BALANCE SHEETS

v3.20.4
CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 31, 2020
Dec. 31, 2019
Current assets    
Cash and cash equivalents $ 56,882,000 $ 50,412,000
Marketable securities - available-for-sale debt securities 311,335,000 39,130,000
Accounts receivable, net of allowance for doubtful accounts of $0 and $0 139,000  
Other current assets and prepaid expenses (including current portion of clinical materials) 29,796,000 30,947,000
Total current assets 398,152,000 120,489,000
Restricted cash 4,602,000 4,496,000
Clinical materials 2,503,000
Operating lease right-of-use assets, net of accumulated amortization 18,880,000 20,789,000
Property, plant and equipment, net of accumulated depreciation 27,778,000 31,068,000
Intangibles, net of accumulated amortization 1,730,000 2,198,000
Total assets 451,142,000 181,543,000
Current liabilities    
Accounts payable 6,389,000 6,357,000
Operating lease liabilities, current 2,773,000 2,493,000
Accrued expenses and other accrued liabilities 27,079,000 23,363,000
Deferred revenue, current 2,832,000 2,128,000
Total current liabilities 39,073,000 34,341,000
Operating lease liabilities, non-current 20,938,000 22,966,000
Deferred revenue, non-current 49,260,000  
Other liabilities, non-current 644,000 598,000
Total liabilities 109,915,000 57,905,000
Contingencies and commitments - Note 10
Stockholders' equity    
Common stock - Ordinary shares par value ?0.001, 1,038,249,630 authorized and 928,754,958 issued and outstanding (2019: 785,857,300 authorized and 631,003,568 issued and outstanding) 1,325,000 943,000
Additional paid in capital 935,706,000 585,623,000
Accumulated other comprehensive loss (10,048,000) (7,264,000)
Accumulated deficit (585,756,000) (455,664,000)
Total stockholders' equity 341,227,000 123,638,000
Total liabilities and stockholders' equity $ 451,142,000 $ 181,543,000